A new research paper titled "Impact of COVID-19 on the management of patients with metastatic melanoma" has been published in Oncotarget.
Jan 11, 2023
0
39
New research from the University of Colorado (CU) Cancer Center highlights the need for additional data collection for women hoping to have successful pregnancies while undergoing treatment for lung cancer. Specifically, ...
Dec 2, 2022
0
1
Northwestern Medicine investigators have discovered the mechanisms by which a particular protein promotes cancer cell proliferation and survival in acute myeloid leukemia (AML), according to a Northwestern Medicine study ...
Nov 4, 2022
0
11
Stopping prostate cancer cells from morphing into other cell types can overcome the resistance they develop to widely prescribed therapies, a study led by UT Southwestern scientists suggests. The findings, published in Nature ...
Oct 18, 2022
0
37
As more patients with cancer have their tumors genomically profiled, and more therapies targeting genomic alterations enter clinical trials, the task of connecting patients to trials for which they are eligible can be especially ...
Oct 12, 2022
0
35
Chronic obstructive pulmonary disease (COPD) is the most common chronic respiratory disease worldwide and the third leading cause of death. In Germany, about 10% of the population is affected. Fatigue, coughing and persistent ...
Sep 27, 2022
0
126
The advent of small-molecule targeted therapies, a decade ago, revolutionized the treatment of metastatic melanoma, provided that the tumors carry the mutations to respond to these treatments. However, despite a remarkable ...
Sep 22, 2022
0
31
The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of ...
Sep 13, 2022
0
20
In the war against cancer, one of the most critical battles is waged on a cellular level as T cells from the immune system are altered in the lab to attack cancer cells. This form of immunotherapy, called chimeric antigen ...
Aug 25, 2022
0
69
The highly selective RET inhibitor pralsetinib was well-tolerated and demonstrated robust, durable responses in patients with RET fusion-positive cancers regardless of tumor type, according to results from the international ...
Aug 12, 2022
0
36
